Clinical performance of the BD onclarity extended genotyping assay for the management of women positive for human papillomavirus in cervical cancer screening

KD Volesky, S Magnan, MH Mayrand, SD Isidean… - … Biomarkers & Prevention, 2022 - AACR
Background: Among women whose cervical specimens tested positive for high-risk human
papillomaviruses (hrHPV) via the Hybrid Capture 2 assay in the Canadian Cervical Cancer …

The importance of high-risk human papillomavirus types other than 16 and 18 in cervical neoplasia

IA Robadi, M Pharaon… - Archives of pathology & …, 2018 - meridian.allenpress.com
Context.—Types 16 and 18 are the most widely studied high-risk types of human
papillomavirus (HPV). However, other high-risk HPV types (HPV non-16/18) also play a …

Prevalence of human papillomavirus infection among women in rural Nepal

S Shakya, U Syversen, BO Åsvold… - Acta obstetricia et …, 2017 - Wiley Online Library
Introduction In this study we aimed to determine the overall and type‐specific prevalence of
cervical human papillomavirus (HPV) infection and risk factors for such infection among …

[HTML][HTML] Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial

MH Stoler, TC Wright Jr, V Parvu, K Yanson… - Gynecologic …, 2023 - Elsevier
Abstract Objectives The Onclarity cervical cancer screening trial was designed to establish
the clinical validity of the Onclarity HPV assay for extended genotyping (xGT) during …

Accelerating cervical cancer screening with human papillomavirus genotyping

GF Sawaya, M Saraiya, A Soman, SV Gopalani… - American Journal of …, 2023 - Elsevier
Introduction Selective utilization of human papillomavirus (HPV) genotyping in cervical
cancer screening can accelerate clinical management, leading to earlier identification and …

Machine learning interpretation of extended human papillomavirus genotyping by Onclarity in an Asian cervical cancer screening population

OGW Wong, IFY Ng, OKL Tsun, HH Pang… - Journal of Clinical …, 2019 - Am Soc Microbiol
This study aimed (i) to compare the performance of the BD Onclarity human papillomavirus
(HPV) assay with the Cobas HPV test in identifying cervical intraepithelial neoplasia 2/3 or …

The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening

F Song, H Du, C Wang, X Huang, X Qu… - Journal of medical …, 2021 - journals.sagepub.com
Objective The performance of Cobas4800 cycle threshold value (Ct-value, reflecting viral
load) combined with human papillomavirus (HPV) 16/18 genotyping was explored as a …

Good performance of p16/Ki‐67 dual‐stain cytology for detection and post‐treatment surveillance of high‐grade CIN/VAIN in a prospective, cross‐sectional study

W Liu, J Gong, H Xu, D Zhang, N Xia, H Li… - Diagnostic …, 2020 - Wiley Online Library
Background The limited sensitivity of Papanicolaou (Pap) cytology and the low specificity of
HPV testing in detecting cervical or vaginal lesions means that either precancers are missed …

Extended Genotyping to Stratify the Risk of CIN2+ in Women with Persistent HPV Infection, Negative Cytology and Type 3 Transformation Zone

MT Bruno, G Valenti, AG Cavallaro, I Palermo, T Aiello… - Cancers, 2024 - mdpi.com
Simple Summary Persistently hrHPV-positive women with negative cytology and zone
transformation type 3 are at increased risk of being diagnosed with CIN2+. The presence of …

Risk Profile of High-grade Cervical Lesions and Cervical Cancer Considering the Combination of Cytology, HPV Genotype, and Age among Women Undergoing …

JC Possati-Resende, TZ Fritsch… - Revista Brasileira de …, 2023 - thieme-connect.com
Objective The present study aims to establish a risk profile for high-grade cervical lesions
and cervical cancer (CIN2+) in women undergoing colposcopy at the Hospital do Câncer de …